S309 monoclonal antibody
Jump to navigation
Jump to search
Mechanism of action
- S309 human monoclonal SARS CoV antibody cross neutralizes SARS CoV-2 via binding to the receptor(ACE2)-binding domain of the spike glyoprotein[1]
- S309 may be useful for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease[1]
- the question is how does the antibody get onto the epithelial surfaces, especially the upper & lower respiratory tracts
- is it an IgA?
More general terms
References
- ↑ 1.0 1.1 1.2 Pinto D, Park YJ, Beltramello M et al Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. May 18, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32422645 https://www.nature.com/articles/s41586-020-2349-y